A 16-Week, Phase 1, Multicenter, Double-Blind, Randomized, Naproxen and Ibuprofen-Controlled, Parallel-Group Pharmacological Study, to Assess the Effect of Naproxcinod (375mg and750mg, Bid) Compared to Doses of Naproxen (250mg and 500mg, Bid) and to Ibuprofen (600mg, Tid) on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients With Controlled Essential Hypertension.

Trial Profile

A 16-Week, Phase 1, Multicenter, Double-Blind, Randomized, Naproxen and Ibuprofen-Controlled, Parallel-Group Pharmacological Study, to Assess the Effect of Naproxcinod (375mg and750mg, Bid) Compared to Doses of Naproxen (250mg and 500mg, Bid) and to Ibuprofen (600mg, Tid) on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients With Controlled Essential Hypertension.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2011

At a glance

  • Drugs Ibuprofen; Naproxcinod; Naproxen
  • Indications Hypertension; Musculoskeletal pain; Osteoarthritis
  • Focus Pharmacodynamics
  • Sponsors NicOx
  • Most Recent Events

    • 30 Sep 2010 Results presented at the 23rd Scientific Meeting of the International Society of Hypertension.
    • 17 Aug 2010 Resutls reported at 20th European Meeting on Hypertension.
    • 04 May 2010 Results presented as a poster at the 25th Annual Scientific Meeting of the American Society of Hypertension (ASH), held in New York, New York, USA on 1-4 May 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top